Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release

Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In

New Case Studies Highlight Niche Patient Population Identification and Analysis for Portfolio Decision-making Using Epi Analyzer

Download PDF

LONDON, BOSTON, TOKYO (July 20, 2017) — Today life science commercial intelligence leader, Evaluate, released case studies highlighting the value of granular patient segmentation and epidemiological data to support commercial valuations, whitespace identification and product differentiation ultimately leading to enhanced portfolio decision-making. Therapy areas covered include: CAR-T, MPS-III and Age-related Macular Degeneration.

According to report author and Evaluate Senior Analyst Chris Watson, PhD, the last 5 years have witnessed a significant re-organisation of the pharmaceutical business model around the ability to identify, develop and bring to market novel therapies with proven clinical benefits in very well defined patient populations.

“Within this rapidly changing environment, Evaluate is supporting our clients with pioneering approaches to risk / value assessments and forecasting, aimed to improve the quality and speed of analysis for strategic decisions”, said Antonio Iervolino, Head of Forecasting at Evaluate.

The case studies provide practical examples aimed at competitive intelligence, business developers, corporate strategists and executive decision-makers and demonstrate the value to these roles of convenient, high quality epidemiology data used in conjunction with global commercial intelligence.

Epi Analyzer, brings together Evaluate’s expertise in consensus forecasts with a highly granular epidemiology database. Its coverage includes over 160 diseases and 8,000 subpopulations with the ability to drill down to very specific patient pools. To learn more and download the case studies report, please visit: www.evaluate.com/EpiAnalyzerReport2017.

About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2022. Our subscription services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Evaluate's Custom Services provide project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving your daily opinion and insights. The Evaluate service enable the life science community to make sound business decisions about value and opportunity.

For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.

Back to Press Releases